Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 RELAPSE/REFRACTORY B-CELL LYMPHOMA. 4 2021-06-10
CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. Recruiting

2024-510815-30-00 Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia 1 2021-06-02
Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ… Recruiting

2024-515063-66-00 Early stage classical Hodgkin Lymphoma (cHL) without bu 4 2021-03-30
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Higher-risk-myelodysplastic syndromes 5 2020-11-27
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transdu… Recruiting

2024-513901-30-00 Sickle-cell disease 5 2020-11-03
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Treatment of chronic lymphocytic leukaemia with venetoclax and acalabrutinib in case of return of the disease after previous treatment with … Recruiting

2023-505449-18-00 Patients with relapsed CLL 4 2020-07-23
Selinexor, Dexamethasone and Bortezomib in Patients with Multiple Myeloma Recruiting

2024-511608-18-00 Penta-refractory multiple myeloma and triple-class refr 4 2020-06-25
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Acute Myeloid Leukemia (LMA) with FLT3 mutation 5 2020-04-24
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1… Recruiting

2024-515504-39-00 Patients with hematological malignancies (Cf. inclusion 7 2020-02-09
An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibito… Recruiting

2024-516741-39-00 Haemophilia A 6 2020-01-14
MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib Recruiting

2024-513766-20-00 Hematological malignancies 9 2019-12-03
A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting

2023-509699-41-00 Recurrent or Refractory Leukemias, Lymphomas, and Solid 9 2019-11-22
Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients Recruiting

2023-508689-14-00 Sickle cell disease 5 2019-09-16
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retrovir… Recruiting

2024-516832-82-00 Accute lymphoblastic leukemia recurrent, Non-Hodgkin´s 9 2018-08-27
A multicenter trial where patients with CML stop medication a second time. Recruiting

2024-515409-25-00 Chronic myeloid leukemia 4 2018-01-11
CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 All patients who have been treated with Novartis or Pen 5 2017-07-19
Long-term follow-up of the WAS gene therapy study Recruiting

2024-512680-31-00 Treatment of Wiskott-Aldrich Syndrome 4 2014-10-29
Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended

2024-516873-57-00 Acute myeloid leukemia in adults aged 18 to 60 10 2026-01-13
Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicent… Ended

2024-515292-35-00 Acute Myeloid Leukemia 4 2026-01-09
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease Ended

2024-519746-70-01 Sickle Cell Disease 4 2025-09-15
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS Ended

2023-510479-72-00 Relapsed/Refractory AML or Higher-Risk MDS 3 2025-08-05
Evaluation of the efficacy and safety of drug treatment in familial polycythemia associated with an EPO gene mutation: a multicentre, open-l… Ended

2025-521906-16-00 familial polycythemia associated with an EPO gene mutat 3 2025-08-01
A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended

2023-509338-21-00 Primary immune thrombocytopenia 4 2025-05-28